- Stocks
- Healthcare
- NASDAQ: DNLI

Price (delayed)

$22.86

Market cap

$3.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$3.25B

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing

The EPS has soared by 68% YoY and by 12% from the previous quarter

The net income has soared by 63% year-on-year and by 5% since the previous quarter

DNLI's revenue has soared by 191% year-on-year but it is down by 11% since the previous quarter

Denali Therapeutics's gross profit has surged by 191% YoY but it has decreased by 11% QoQ

The quick ratio has declined by 15% since the previous quarter

What are the main financial stats of DNLI

Market
Valuations
Earnings

Shares outstanding

142.61M

Market cap

$3.26B

Enterprise value

$3.25B

Price to earnings (P/E)

N/A

Price to book (P/B)

2.19

Price to sales (P/S)

11.56

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

11

Revenue

$295.39M

EBIT

-$137.22M

EBITDA

-$128.37M

Free cash flow

-$425.11M

Per share
Balance sheet
Liquidity

EPS

-$0.93

Free cash flow per share

-$2.85

Book value per share

$10.46

Revenue per share

$1.98

TBVPS

$10.58

Total assets

$1.58B

Total liabilities

$125.62M

Debt

$50.55M

Equity

$1.46B

Working capital

$890.99M

Debt to equity

0.03

Current ratio

11.79

Quick ratio

11.34

Net debt/EBITDA

0.08

Margins
Efficiency
Dividend

EBITDA margin

-43.5%

Gross margin

100%

Net margin

-46.5%

Operating margin

-65.5%

Return on assets

-10.4%

Return on equity

-11.5%

Return on invested capital

-11.6%

Return on capital employed

-9.2%

Return on sales

-46.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Denali Therapeutics stock price performed over time

Intraday

-1%

1 week

8.14%

1 month

6.13%

1 year

-22.4%

YTD

6.52%

QTD

-1.55%

How have Denali Therapeutics's revenue and profit performed over time

Revenue

$295.39M

Gross profit

$295.39M

Operating income

-$193.6M

Net income

-$137.25M

Gross margin

100%

Net margin

-46.5%

DNLI's revenue has soared by 191% year-on-year but it is down by 11% since the previous quarter

Denali Therapeutics's gross profit has surged by 191% YoY but it has decreased by 11% QoQ

Denali Therapeutics's net margin has soared by 87% YoY but it has decreased by 6% from the previous quarter

DNLI's operating margin has surged by 83% year-on-year but it is down by 10% since the previous quarter

What is Denali Therapeutics's growth rate over time

What is Denali Therapeutics stock price valuation

P/E

N/A

P/B

2.19

P/S

11.56

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

11

The EPS has soared by 68% YoY and by 12% from the previous quarter

DNLI's price to book (P/B) is 52% less than its 5-year quarterly average of 4.6 and 19% less than its last 4 quarters average of 2.7

Denali Therapeutics's equity has surged by 51% YoY and by 41% QoQ

DNLI's revenue has soared by 191% year-on-year but it is down by 11% since the previous quarter

The stock's price to sales (P/S) is 73% less than its 5-year quarterly average of 43.1 but 17% more than its last 4 quarters average of 9.9

How efficient is Denali Therapeutics business performance

The ROS has soared by 87% YoY but it has decreased by 6% from the previous quarter

The return on invested capital has surged by 72% year-on-year and by 15% since the previous quarter

The return on equity has surged by 71% year-on-year and by 15% since the previous quarter

The return on assets has surged by 62% year-on-year and by 9% since the previous quarter

What is DNLI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for DNLI.

How did Denali Therapeutics financials performed over time

DNLI's total liabilities has dropped by 72% year-on-year but it is up by 2.2% since the previous quarter

The company's total assets rose by 37% QoQ and by 12% YoY

Denali Therapeutics's debt is 97% less than its equity

Denali Therapeutics's equity has surged by 51% YoY and by 41% QoQ

DNLI's debt to equity has dropped by 50% year-on-year and by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.